Clinical trials: Choroid Diseases
Polypoidal Choroidal Vasculopathy
Safety Study of High-Dose Ranibizumab for Polypoidal Choroidal Vasculopathy
Monthly, continuous anti-vegf therapy for patients presenting with active polypoidal choroidal vasculopathy. Two arms, treatment naive and previously treated with an FDA approved anti-VEGF therapy, will be randomized and dosed…
- Trial name
- PEARL2 (NCT01248117)
- Testing
- ranibizumab 2.0mg
- Where
- 2 sites in United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Retina Consultants of Hawaii
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Temozolomide and O6-benzylguanine in Treating Children With Solid Tumors
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00020150
- Testing
- O6-benzylguanine, temozolomide
- Where
- United States
- Sponsor
- National Cancer Institute (NCI)
Age-related Macular Degeneration (ARMD)
Switching to Aflibercept 8mg in Patients Showing Limited Response to Previous Treatment
The treatment landscape for neovascular AMD has evolved with various anti-VEGF agents since 2006. Ranibizumab initially led the way, but its limited efficacy in reducing retinal edema paved the way for aflibercept in 2011, which…
- Trial name
- NCT06683950
- Testing
- Aflibercept 8mg
- Where
- South Korea
- Volunteers
- 35 people
- Sponsor
- Kim's Eye Hospital
Cancer
MS-275 in Treating Patients With Advanced Solid Tumors or Lymphoma
RATIONALE: MS-275 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. PURPOSE: This phase I trial is studying the side effects and best dose of MS-275 in treating patients with advanced solid…
- Trial name
- NCT00020579
- Testing
- entinostat
- Where
- 3 sites in United States
- Volunteers
- 75 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Healthy
Clinical Assessment of Barley and Oat Phytochemicals
The goal of this placebo-controlled, 3-way crossover study is to determine the acute (24-h) bioavailability and pharmacokinetics of the major phytochemicals found whole barley and oats, as well as their effects on selected…
- Trial name
- NCT01303562
- Testing
- Whole grain oats and barley
- Where
- United States
- Volunteers
- 13 people, healthy volunteers welcome
- Sponsor
- Tufts University
Brain and Central Nervous System Tumors, Neuroblastoma
Combination Chemotherapy With or Without Radiation Therapy in Treating Children With Brain Tumors
RATIONALE: Drugs used in chemotherapy work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00281905
- Testing
- carboplatin, cisplatin, cyclophosphamide
- Where
- 21 sites in Ireland, United Kingdom
- Volunteers
- 50 people
- Sponsor
- Children's Cancer and Leukaemia Group
Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting
Acupressure in Controlling Nausea in Young Patients Receiving Highly Emetogenic Chemotherapy
RATIONALE: Acupressure wristbands may prevent or reduce nausea and caused by chemotherapy. It is not yet known whether standard care is more effective with or without acupressure wristbands in controlling acute and delayed…
- Conditions
- Central Nervous System Tumor, Pediatric, Chemotherapy-induced Nausea and Vomiting, Unspecified Childhood Solid Tumor, Protocol Specific
- Trial name
- SCUSF1202 (NCT01346267)
- Testing
- Real Acupressure Band
- Where
- 25 sites in United States, Canada
- Volunteers
- 187 people
- Sponsor
- University of South Florida
Birdshot Chorioretinopathy, Posterior Uveitis
Birdshot Chorioretinopathy : Prospective Follow-up and Immunogenetic Studies(CO-BIRD)
The purpose of this study is twofold: 1. To analyze the clinical features of a cohort of patients with birdshot chorioretinopathy (BCR), an inflammatory bilateral ocular disease, affecting the choroid and the retina.
- Trial name
- CO-BIRD (NCT05153057)
- Testing
- Observational study
- Where
- France
- Volunteers
- 600 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size
Dacarbazine and Recombinant Interferon Alfa-2b in Treating Patients With Primary Uveal Melanoma With Genetic Imbalance
RATIONALE: Drugs used in chemotherapy, such as dacarbazine, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Ciliary Body and Choroid Melanoma, Medium/Large Size, Ciliary Body and Choroid Melanoma, Small Size, Iris Melanoma, Recurrent Intraocular Melanoma
- Trial name
- NCT01100528
- Testing
- recombinant interferon alfa-2b, dacarbazine, laboratory biomarker analysis
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Case Comprehensive Cancer Center
Neovascular Age-Related Macular Degeneration
A Depot Formulation of Sunitinib Malate (GB-102) in Subjects With Neovascular (Wet) Age-related Macular Degeneration
The purpose of this study is to evaluate the safety and efficacy of single and repeated intravitreal injections of GB-102 in subjects with neovascular (wet) age-related macular degeneration.
- Trial name
- NCT03249740
- Testing
- GB-102, Aflibercept
- Where
- 8 sites in United States
- Volunteers
- 32 people
- Sponsor
- Graybug Vision
Intraocular Melanoma, Melanoma (Skin)
Temozolomide and Thalidomide in Treating Patients With Stage III or Stage IV Melanoma
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Thalidomide may stop the growth of melanoma by stopping blood flow to the tumor.
- Trial name
- NCT00005815
- Testing
- temozolomide, thalidomide
- Where
- United States
- Sponsor
- Memorial Sloan Kettering Cancer Center
Choroidal Neovascularization, Macular Degeneration
Phase I Study of Corticosteroid Treatment of Ill-Defined Choroidal Neovascularization in Age-Related Macular Degeneration
Age-related macular degeneration (AMD) represents the most common cause of blindness in patients over the age of 60. The major cause of vision loss in this disease is due to the development of choroidal neovascular membrane…
- Trial name
- NCT00001615
- Testing
- Corticosteroid
- Where
- United States
- Volunteers
- 180 people
- Sponsor
- National Eye Institute (NEI)
Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor
Ixabepilone in Treating Young Patients With Solid Tumors or Leukemia That Haven't Responded to Therapy
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of ixabepilone in treating young…
- Conditions
- Brain and Central Nervous System Tumors, Childhood Germ Cell Tumor, Extragonadal Germ Cell Tumor, Kidney Cancer
- Trial name
- NCT00030108
- Testing
- ixabepilone
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- National Institutes of Health Clinical Center (CC)
Intraocular Melanoma
Paclitaxel Albumin-Stabilized Nanoparticle Formulation in Treating Patients With Metastatic Melanoma of the Eye That Cannot Be Removed By Surgery
RATIONALE: Drugs used in chemotherapy, such as paclitaxel albumin-stabilized nanoparticle formulation, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Trial name
- NCT00738361
- Testing
- nab-paclitaxel
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Polypoidal Choroidal Vasculopathy
Double-dose Ranibizumab for Polypoidal Choroidal Vasculopathy
The purpose of this study is to determine whether double-dose Ranibizumab are effective to regress the polyps and benefit to the visual outcome in the polypoidal choroidal vasculopathy (PCV).
- Trial name
- NCT02769169
- Testing
- Lucentis® (Raibizumab) double-dose, Lucentis® (Raibizumab) regular-dose
- Where
- 4 sites in China
- Volunteers
- 5 people
- Sponsor
- Sun Yat-sen University
Age-related Macular Degeneration
Efficacy and Safety Study of Squalamine Ophthalmic Solution in Subjects With Neovascular AMD
A Phase 3 Study of the Efficacy and Safety of Squalamine Lactate Ophthalmic Solution 0.2% Twice Daily in Subjects with Neovascular Age-Related Macular Degeneration. Patients will receive injections of ranibizumab.
- Trial name
- MAKO (NCT02727881)
- Testing
- Squalamine lactate ophthalmic solution, 0.2%, ranibizumab
- Where
- 118 sites in United States
- Volunteers
- 230 people
- Sponsor
- Ohr Pharmaceutical Inc.
Gyrate Atrophy
Gene Therapy for Gyrate Atrophy
This study will evaluate the safety and effectiveness of gene therapy for patients with gyrate atrophy, an inherited condition in which areas of the retina-the inner lining of the wall of the eye-become thin.
- Trial name
- NCT00001735
- Testing
- Gene therapy
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- National Eye Institute (NEI)
Major Depressive Disorder (MDD)
The Effect of Transcranial Magnetic Stimulation Treatment on Microvasculature Stracture of the Retina and the Choroid
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option in treatment-resistant depression.
- Trial name
- TMS_OCT-A (NCT06708013)
- Testing
- Transcranial Magnetic Stimulation
- Where
- Turkey (Türkiye)
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Gulhane Training and Research Hospital
Pseudoxanthoma Elasticum
Evolution of Visual Impairment During Pseudoxanthoma Elasticum
Pseudoxanthoma elasticum is a disease whom frequency is estimated about 1/50000 to 1/100 000. There is a female preponderance with a sex-ratio of 2:1.
- Trial name
- NCT00555113
- Where
- France
- Volunteers
- 38 people
- Sponsor
- European Georges Pompidou Hospital
Choroidal Neovascularization, Mineralocorticoid Excess
Biomarkers and Choroidal Neovascularization
The aim of the study is to find biomarkers in the blood and aqueous humor of patients with type 1 choroidal neovascularization and correlate them with the response to anti-VEGF treatment.
- Trial name
- BioNéoRet (NCT04439708)
- Testing
- Blood and aqueous humor biomarker of treatment response
- Where
- 2 sites in France
- Volunteers
- 250 people
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France